VANGL planar cell polarity protein 1 (VANGL1)

VANGL planar cell polarity protein 1 (VANGL1) is a core component of the planar cell polarity (PCP) pathway, essential for regulating coordinated orientation and alignment of cells across epithelial tissues perpendicular to the apical-basal axis[7]. It is a tetraspanin (four-pass transmembrane) protein localized at the cell membrane and oligomerizes as dimers of trimers, interacting principally with the PCP effector Prickle1 (PK1)[2][4][7]. VANGL1 is critical for tissue morphogenesis, neural tube closure, and collective cell migration, especially during embryogenesis[2][3][4][5][6][7]. Disease-associated mutations disrupt its interactions and/or oligomerization, leading to defects such as neural tube defects and increasing susceptibility to certain cancers[2][5][7]. Although currently not the direct pharmacological target of approved therapeutics or a validated biomarker for drug efficacy, its mutation status is clinically relevant for risk prediction in congenital malformations and some cancers[5][6][7].

Other names

Vang-like protein 1STB2LPP2Loop-tail protein 2 homologStrabismus 2Van Gogh-like protein 1KITENINSTBM2vang-like protein 1KAI1 C-terminal interacting tetraspaninloop-tail protein 2 homologstrabismus 2van Gogh-like protein 1vang-like 1 (van gogh, Drosophila)VANGL1

Currently, no approved drugs are documented as targeting VANGL1 directly; thus, mechanisms of action for pharmacological agents cannot be specified